Spartanburg Regional Healthcare System (SRHS) in the US has chosen AccessDx Laboratory as its partner for a pharmacogenomics (PGx) programme.
The collaboration will enable SRHS to provide PGx testing for employees and patients, helping clinicians pinpoint potentially dangerous drug-gene interactions and optimise medication efficacy.
AccessDx Laboratory focuses on health equity via analysis of rare genetic variants and can integrate lab results directly into its EHR.
AccessDx Laboratory CEO Bryon Cipriani said: “PGx testing benefits patients in all stages of their care journeys, throughout their lifetimes, and across the continuum of care.
“SRHS distinguishes itself through its embrace of precision medicine across all care disciplines, evidenced by its commitment to helping deliver discrete drug-gene insights at providers’ fingertips and supporting effective utility with educational resources and publications.”
The programme is set to educate care teams, clinical leaders, patients, and communities on AccessDx Laboratory experts’ drug-gene insight and research findings through content and training courses.
SRHS aims to use peer-reviewed strategies and guidelines for risk assessment and testing to deliver point-of-care insights.
Under this programme, patients and providers will benefit from PGx’s value in guiding specific treatments.
SRHS executive vice-president and chief operating officer Charles Morrow said: “This collaboration enables SRHS clinicians to deliver better care to those within our community and ensures local residents can benefit from impactful, precision medicine-based treatments in their own hospital/care centre, without having to travel elsewhere.”
The PGx programme will be introduced in various clinical settings, including family practice, oncology, maternal-foetal medicine, behavioural health, and paediatrics, with a goal to extend across all specialities by 2025.
SRHS implemented the 2bPrecise enterprise platform last month to enhance care and genomics integration within the healthcare system.
